BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) — Patients transitioning from federal prison to Federal Residential Reentry Centers now have access to injectable buprenorphine (Sublocade) through Bicycle Health, the nation’s largest provider of telemedicine treatment for opioid use disorder (OUD), in collaboration with Wellpath, the leading provider of compassionate care to vulnerable patients in challenging clinical environments. In February 2023, Wellpath entered into an affiliation agreement with Bicycle Health to offer virtual Medication for Opioid Use Disorder (MOUD) treatment to Wellpath patients.

Injectable buprenorphine (Sublocade) is a widely used form of MOUD for adults in custody. Wellpath patients receiving MOUD care with Sublocade during incarceration can now seamlessly continue their MOUD treatment without interruptions when transitioning to reentry centers (halfway houses) served by Bicycle Health. Injectable buprenorphine is administered monthly, making it less susceptible to treatment interruptions compared to oral buprenorphine, which is often difficult to access and must be taken daily.

“Our collaboration with Bicycle Health allows us to offer telemedicine-first treatment options, which have become the gold standard for OUD treatment and exceed community care standards. This is especially crucial for our patients during their vulnerable period,” says Dr. Thomas Pangburn, Chief Clinical Officer at Wellpath. “Our goal is to keep these patients alive and out of prison, knowing that recidivism rates decrease by nearly 25 percent when incarcerated individuals have access to MOUD treatment.”